To discriminate immunotherapeutic responders from nonresponders, several useful biomarkers such as PD‐L1 expression, tumor mutational burden (TMB), tumor‐infiltrating phenotypes, and the microbiome pattern of patients have been identified.10 However, some of these biomarkers still lack enough stability for the prediction of immunotherapeutic responses. The gene discussed is CD274; the disease is neoplasm.